Products & Services
Applications

Applications

Nanopore sequencing offers advantages in all areas of research. Our offering includes DNA sequencing, as well as RNA and gene expression analysis and future technology for analysing proteins.

Learn about applications
View all Applications
Resources
News Explore
Contact
Back

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

Publication

Date: 21st January 2021 | Source: Cell

Authors: Philip J. M. Brouwer, Mitch Brinkkemper, Pauline Maisonnasse, Nathalie Dereuddre-Bosquet, Marloes Grobben, Mathieu Claireaux, Marlon de Gast, Romain Marlin, Virginie Chesnais, Ségolène Diry, Joel D. Allen, Yasunori Watanabe, Julia M. Giezen, Gius Kerster,, Hannah L. Turner, Karlijn van der Straten, Cynthia A. van der Linden, Yoann Aldon, Thibaut Naninck, Ilja Bontjer, Judith A. Burger, Meliawati Poniman, Anna Z. Mykytyn, Nisreen M. A. Okba, Edith E. Schermer, Marielle J. van Breemen, Rashmi Ravichandran,, Tom G. Caniels, Jelle van Schooten, Nidhal Kahlaoui, Vanessa Contreras, Julien Lemaître, Catherine Chapon, Raphaël Ho Tsong Fang, Julien Villaudy, Kwinten Sliepen, Yme U. van der Velden, Bart L. Haagmans, Godelieve J. de Bree, Eric Ginoux, Andrew B. Ward,, Max Crispin, Neil P. King, Sylvie van der Werf, Marit J. van Gils, Roger Le Grand, Rogier W. Sanders.

The SARS-CoV-2 pandemic is continuing to disrupt personal lives, global healthcare systems and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission and disease.

Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein.

Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits and cynomolgus macaques. The vaccine-induced immunity protected macaques against a high dose challenge, resulting in strongly reduced viral infection and replication in upper and lower airways.

These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic.

Read the full text

Recommended for you

Open a chat to talk to our sales team
FAQs

FAQs

Search